Sponsor
Tibotec Pharmaceuticals, Ireland
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Tibotec Pharmaceuticals, Ireland appears in 45 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
45 shownTMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.NCT01336829 · lead sponsor · 2011-03-01
COMPLETEDTMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and RaltegravirNCT01288755 · lead sponsor · 2011-02-01
COMPLETEDTMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted ConditionsNCT01308658 · lead sponsor · 2011-01-01
COMPLETEDTMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected PatientsNCT01090648 · lead sponsor · 2010-03-01
COMPLETEDTMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed ConditionsNCT01052883 · lead sponsor · 2010-03-01
COMPLETEDTMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278NCT01031589 · lead sponsor · 2010-01-01
COMPLETEDTMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy VolunteersNCT01001247 · lead sponsor · 2010-01-01
COMPLETEDA Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected ChildrenNCT00919854 · lead sponsor · 2009-09-01
COMPLETEDA Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected AdolescentsNCT00915655 · lead sponsor · 2009-07-01
COMPLETEDA Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected PatientsNCT00838162 · lead sponsor · 2009-06-01
COMPLETEDPEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.NCT00908414 · lead sponsor · 2009-05-01
WITHDRAWNTMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.NCT00828815 · lead sponsor · 2009-03-01
COMPLETEDPEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral DarunavirNCT00838760 · lead sponsor · 2009-02-01
COMPLETEDTMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet FormulationNCT00812292 · lead sponsor · 2009-01-01
COMPLETEDInnovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629NCT00854204 · lead sponsor · 2008-11-01
COMPLETEDTMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and AdolescentsNCT00665847 · lead sponsor · 2008-11-01
COMPLETEDTMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.NCT00744770 · lead sponsor · 2008-10-01
COMPLETEDTMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.NCT00740389 · lead sponsor · 2008-09-01
COMPLETEDTMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.NCT00767117 · lead sponsor · 2008-09-01
COMPLETEDTMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.NCT00744887 · lead sponsor · 2008-08-01
COMPLETEDTMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.NCT00739622 · lead sponsor · 2008-07-01
COMPLETEDTMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.NCT00741741 · lead sponsor · 2008-07-01
TERMINATEDTMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.NCT00736905 · lead sponsor · 2008-06-01
COMPLETEDTMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase InhibitorsNCT00543725 · lead sponsor · 2008-06-01
COMPLETEDTMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.NCT00540449 · lead sponsor · 2008-05-01
COMPLETEDA Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)NCT00524368 · lead sponsor · 2007-10-01
COMPLETEDTMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) PreviouslyNCT00513513 · lead sponsor · 2006-09-01
TERMINATEDA Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and AdolescentsNCT00355524 · lead sponsor · 2006-06-01
COMPLETEDTMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.NCT00255099 · lead sponsor · 2005-12-01
COMPLETEDTMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.NCT00254046 · lead sponsor · 2005-11-01
COMPLETEDTMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.NCT00258557 · lead sponsor · 2005-09-01
COMPLETEDTMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment OptionsNCT00115050 · lead sponsor · 2005-06-01
COMPLETEDA Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 StudyNCT00128830 · lead sponsor · 2005-06-01
COMPLETEDA Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral MedicinesNCT00110305 · lead sponsor · 2005-06-01
COMPLETEDTMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced PatientsNCT00110877 · lead sponsor · 2005-04-01
COMPLETEDTMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI UseNCT00225303 · lead sponsor · 2005-03-01
COMPLETEDA Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 TrialsNCT02187107 · lead sponsor · 2005-01-01
COMPLETEDTMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 TrialNCT00111280 · lead sponsor · 2004-09-01
COMPLETEDTMC125-C223: TMC125 in HIV-1 Infected SubjectsNCT00081978 · lead sponsor · 2004-03-01
COMPLETEDAn Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.NCT00081588 · lead sponsor · 2003-11-01
COMPLETEDTMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.NCT00650832 · lead sponsor · 2003-10-01
COMPLETEDTMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected PatientsNCT00071097 · lead sponsor · 2003-10-01
COMPLETEDTMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected PatientsNCT00412646 · lead sponsor · 2002-06-01
COMPLETEDTMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) StrainsNCT00964327 · lead sponsor · 2001-08-01
COMPLETEDTMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.NCT00245739 · lead sponsor
APPROVED_FOR_MARKETINGSponsor roles
lead sponsor45
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.